Abstract: Objective To evaluate the clinical efficacy of bevacizumab for pterygium treatment. Design Meta-analysis. Participants The randomized controled trials on the efficacy and complications in treatment of pterygium by bevacizumab. Methods Search was conducted in Pubmed, EMbase, Cochrane Library, CNKI, Wanfang database, CBM and VIP, and hand-search was also performed．The qualities of the randomized controlled trials (RCT) were evaluated according to the Cochrane Handbook for Systematic Reviews of Interventions Version 5.0. The softwares RevMan 5.0 and SPSS10.0 were used for Meta-analysis． Main Outcome Measures The Odds ratio(OR) of the recurrence rate and the complications in treatment of pterygium by bevacizumab. Results Only 7 trials were included, involving 398 eyes. Meta-analysis showed that significant difference was not found between the bevacizumab and the control in recurrence [OR=0.60, 95%CI(0.34-1.05), P=0.07, I2=7%]. There was also no difference in reducing the complications[OR=0.68, 95％CI(0.38-1.22), P=0.19,  I2=0%]． Conclusion Bevacizumab in pterygium treatment does not reduce pterygium recurrence．

Key words: pterygium/therapy, Bevacizumab, Meta-analysis